FOXJ1 Gene Identified as Primary Driver of Taxane Chemotherapy Resistance in Advanced Prostate Cancer Patients

Weill Cornell study finds the FOXJ1 gene drives taxane resistance in prostate cancer by altering microtubules, offering a new biomarker for patient treatment.

By: AXL Media

Published: Mar 10, 2026, 12:20 PM EDT

Source: The information in this article was sourced from Weill Cornell Medicine

Uncovering the Mechanism of Chemotherapy Evasion

A significant hurdle in treating metastatic prostate cancer is the eventual development of drug resistance, particularly to taxanes, the only class of chemotherapy shown to extend survival in advanced cases. A collaborative study published in Nature Communications has identified the FOXJ1 gene as a previously unrecognized culprit in this process. While many patients initially respond well to treatment, cancer cells often adapt, rendering the life-prolonging effects of taxanes temporary. This research provides a molecular explanation for this shift, offering a new lens through which clinicians can view tumor evolution.

The Unexpected Role of FOXJ1 in Cellular Scaffolding

Traditionally, the FOXJ1 transcription factor was known for its role in creating cilia—hair-like structures on the surface of cells. However, researchers discovered that in prostate cancer, the gene is co-opted to regulate microtubules, the internal scaffolding and transport tracks essential for cell division. Because taxane drugs work by binding to and stabilizing these microtubules to trigger cell death, any alteration in their behavior can neutralize the medication. When FOXJ1 levels are high, the dynamic nature of these structures changes, preventing the drug from latching on effectively.

Evidence from Resistant Mouse Models and Laboratory Trials

To confirm the gene's impact, the research team developed mouse models that mirrored the human experience of becoming resistant to the drug docetaxel after repeated treatment cycles. Analysis showed that FOXJ1 expression was significantly higher in these resistant tumors compared to those still sensitive to chemotherapy. Further laboratory experiments demonstrated that manually increasing FOXJ1 levels made cancer cells less vulnerable to treatment, while reducing the gene's expression restored the drug's effectiveness, proving that FOXJ1 is a functional "on-off" switch for resistance.